Literature DB >> 27089873

Managing Disability in Progressive Multiple Sclerosis.

Divyanshu Dubey1, Peter Sguigna1, Olaf Stüve2,3.   

Abstract

OPINION STATEMENT: Patients with progressive forms of multiple sclerosis have various symptoms which affect their quality of life significantly including depression, cognitive decline, sleep changes, bladder dysfunction, sexual dysfunction, and spasticity. Despite recent promising results on the effects of ocrelizumab on neurological disability in patients with PPMS, currently none of the immunomodulatory therapies are approved for progressive forms of multiple sclerosis. Therefore, clinicians currently mostly focus on management of well-recognized comorbidities of this disease phenotype in order to improve patients' quality of life. There are very few studies evaluating strategies of symptomatic management on progressive forms of multiple sclerosis and most of the data is derived from studies on relapsing forms of multiple sclerosis. Understanding of the risks, benefits, and limitations of these therapies can significantly affect patient care. In this article, we review common comorbidities associated with progressive forms of multiple sclerosis and outline important strategies for their symptomatic management.

Entities:  

Keywords:  Depression; Gait disorder; Incontinence; Neuropsychiatric manifestations; Primary progressive multiple sclerosis; Secondary progressive multiple sclerosis; Sexual dysfunction; Spasticity

Year:  2016        PMID: 27089873     DOI: 10.1007/s11940-016-0412-7

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  66 in total

Review 1.  Amantadine for fatigue in multiple sclerosis.

Authors:  E Pucci; P Branãs; R D'Amico; G Giuliani; A Solari; C Taus
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 2.  Spasticity management in multiple sclerosis.

Authors:  Christina Hughes; Ileana M Howard
Journal:  Phys Med Rehabil Clin N Am       Date:  2013-11       Impact factor: 1.784

3.  Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis.

Authors:  Orjana Velikonja; Katarina Curić; Ana Ozura; Sasa Sega Jazbec
Journal:  Clin Neurol Neurosurg       Date:  2010-04-04       Impact factor: 1.876

4.  Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.

Authors:  P M Rossini; P Pasqualetti; C Pozzilli; M G Grasso; E Millefiorini; A Graceffa; G A Carlesimo; G Zibellini; C Caltagirone
Journal:  Mult Scler       Date:  2001-12       Impact factor: 6.312

5.  Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.

Authors:  B Stankoff; E Waubant; C Confavreux; G Edan; M Debouverie; L Rumbach; T Moreau; J Pelletier; C Lubetzki; M Clanet
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process.

Authors:  Yermi Harel; Nava Appleboim; Mor Lavie; Anat Achiron
Journal:  J Neurol Sci       Date:  2008-09-24       Impact factor: 3.181

7.  Memantine induces reversible neurologic impairment in patients with MS.

Authors:  P Villoslada; G Arrondo; J Sepulcre; M Alegre; J Artieda
Journal:  Neurology       Date:  2008-12-17       Impact factor: 9.910

8.  Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.

Authors:  Valentina Tomassini; Carlo Pozzilli; Emanuela Onesti; Patrizio Pasqualetti; Fabiana Marinelli; Angela Pisani; Cesare Fieschi
Journal:  J Neurol Sci       Date:  2004-03-15       Impact factor: 3.181

9.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Authors:  P Abrams; R Freeman; C Anderström; A Mattiasson
Journal:  Br J Urol       Date:  1998-06

Review 10.  Anti-inflammatory and Antimicrobial Effects of Heat-Clearing Chinese Herbs: A Current Review.

Authors:  Rekik A Muluye; Yuhong Bian; Paulos N Alemu
Journal:  J Tradit Complement Med       Date:  2014-04
View more
  3 in total

1.  Sexual Therapy for Women with Multiple Sclerosis and Its Impact on Quality of Life.

Authors:  Maryam Zamani; Azadeh Tavoli; Behjat Yazd Khasti; Neda Sedighimornani; Masood Zafar
Journal:  Iran J Psychiatry       Date:  2017-01

2.  Reduced Fragmentation of IGFBP-2 and IGFBP-3 as a Potential Mechanism for Decreased Ratio of IGF-II to IGFBPs in Cerebrospinal Fluid in Response to Repeated Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis.

Authors:  Andreas Hoeflich; Brit Fitzner; Christina Walz; Michael Hecker; Armin Tuchscherer; Julia Brenmoehl; Uwe Klaus Zettl
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-05       Impact factor: 5.555

3.  Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis.

Authors:  Andreas Hoeflich; Brit Fitzner; Christina Walz; Michael Hecker; Armin Tuchscherer; Manuela Bastian; Julia Brenmoehl; Ina Schröder; Holger S Willenberg; Martin Reincke; Uwe Klaus Zettl
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-27       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.